77 terminated. 77 Phase 1, 26 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 77 | Terminated 77 |
| Phase 2 | 26 | Terminated 26 |
Follow Pneumonia: new trials by email Literature Review of Pneumonia trials Research Report on Pneumonia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pancoronavirus Vaccine Study in Healthy Adults CoV-RBD-scNP-001 and 3M-052-AF - COVID-19 Respiratory Infection, SARS CoV 2 Infection | Phase 1 | Terminated | Duke University | 4 | 2025-08-01 | 2026-10-19 |
| Safety Study of SLV213 for the Treatment of COVID-19. Placebo for SLV213, SLV213 - COVID-19 | Phase 1 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 16 | 2024-04-09 | 2025-07-22 |
| A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Elarekibep in Healthy Japanese Subjects Elarekibep, Placebo - Healthy Subjects (Indication: Asthma) | Phase 1 | Terminated | AstraZeneca | 30 | 2023-04-11 | 2023-07-18 |
| Safety & Immunogenicity of RVM-V001/RVM-V002 or RVMV001+RVMV002 (Co Administered as Separate Injections) in Healthy Individuals RVM-V001 30 µg, RVM-V002 30 µg, RVM-V001 (15 µg) + RVM-V002 (15 µg) co-administration - Infectious Disease, COVID-19 | Phase 1 / Phase 2 | Terminated | RVAC Medicines (US), Inc. | 24 | 2023-03-22 | 2023-10-16 |
| iCP-NI - Safety, Tolerability, Pharmacokinetic, and Immunogenicity Study in Healthy Male and Female Subjects iCP-NI, Placebo - Healthy Volunteers | Phase 1 | Terminated | Cellivery Therapeutics, Inc. | 24 | 2023-01-19 | 2025-09-19 |
| A 2-Part First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CMTX-101 CMTX-101, Placebo - Community-acquired Pneumonia, Bacterial Pneumonia | Phase 1 | Terminated | Clarametyx Biosciences, Inc. | 28 | 2022-11-14 | 2024-10-21 |
| Safety and Immunogenicity of RVM-V001 in Healthy Individuals Previously Vaccinated With BNT162b2 and mRNA-1273 RVM-V001 10 µg, RVM-V001 30 µg, RVM-V001 60 µg - Infectious Disease, COVID-19 | Phase 1 | Terminated | RVAC Medicines (US), Inc. | 13 | 2022-09-12 | 2023-06-27 |
| A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease PF-07321332 (nirmatrelvir)/ritonavir - COVID-19 | Phase 1 | Terminated | Pfizer | 15 | 2022-09-07 | 2024-09-23 |
| Study to Assess Adverse Events and How Oral ABBV-990 Moves Through the Body of Adult Healthy Participants ABBV-990, Placebo for ABBV-990 - Healthy Volunteers | Phase 1 | Terminated | AbbVie | 24 | 2022-07-25 | 2022-10-27 |
| A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19 nirmatrelvir, ritonavir - COVID-19 | Phase 1 | Terminated | Pfizer | 25 | 2022-06-22 | 2026-08-17 |
| A Study Assessing the Safety, Tolerability, Immunogenicity of COVID-19 Vaccine Candidate PRIME-2-CoV_Beta, Orf Virus Expressing SARS-CoV_2 Spike and Nucleocapsid Proteins PRIME-2-CoV_Beta - SARS-CoV-2 Infection | Phase 1 | Terminated | Speransa Therapeutics | 103 | 2022-06-20 | 2024-02-09 |
| IMM-BCP-01 in Mild to Moderate COVID-19 IMM-BCP-01, Placebo - SARS-CoV2 Infection, COVID-19 | Phase 1 | Terminated | Immunome, Inc. | 9 | 2022-06-03 | 2024-09-26 |
| THEMBA II T-Cell Vaccine: Vaccination With saRNA COVID-19 Vaccines AAHI-SC2 Vaccine, AAHI-SC3 Vaccine, EUA or approved vaccine - COVID-19 | Phase 1 / Phase 2 | Terminated | ImmunityBio, Inc. | 60 | 2022-05-05 | 2025-03-11 |
| Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC) sotrovimab - Covid19 | Phase 1 | Terminated | Vir Biotechnology, Inc. | 316 | 2022-03-28 | 2024-09-19 |
| NanoMn®_COVID-19 A Prospective, Multicenter, Randomized, Placebo-controlled, Parallel-group, Double-blind Trial to Evaluate the Clinical Efficacy of NanoManganese® on Top of Standard of Care, in Adult Patients With Moderate to Severe Coronavirus Disease 2019 (COVID-19) Placebo, Experimental drug - COVID-19 Pandemic | Phase 1 / Phase 2 | Terminated | Medesis Pharma SA | 7 | 2022-02-04 | 2023-10-26 |
| Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study Questionnaire Administration, Sotrovimab, Biospecimen Collection - COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 20 | 2022-01-25 | 2025-02-13 |
| Evaluation of IGM-6268 in Healthy Adults and Patients With Mild to Moderate COVID-19 IGM-6268, Placebo - Healthy Volunteers, COVID-19 | Phase 1 | Terminated | IGM Biosciences, Inc. | 26 | 2022-01-20 | 2022-10-14 |
| ApTOLL for the Treatment of COVID-19 ApTOLL, Saline - COVID-19 | Phase 1 | Terminated | Macarena Hernández Jiménez | 5 | 2022-01-14 | 2023-08-07 |
| Feasibility Pilot Clinical Trial of Omega-3 Supplement vs. Placebo for Post Covid-19 Recovery Among Health Care Workers Omega-3 (EPA+DHA), Placebo - COVID-19 | Phase 1 | Terminated | Hackensack Meridian Health | 32 | 2022-01-10 | 2024-09-19 |
| A Safety, Tolerability, and Efficacy Study of IBI314 in Ambulatory Patients With COVID-19 IBI314, Placebo - COVID-19 | Phase 1 / Phase 2 | Terminated | Innovent Biologics (Suzhou) Co. Ltd. | 248 | 2022-01-06 | 2023-12-18 |
Showing 20 of 77. Sign in to see all of them.
COVID-19 (68) · Coronavirus Infections (9) · Virus Diseases (4) · Community-Acquired Pneumonia (3) · Lung Diseases (3) · Respiratory Distress Syndrome (3) · Acute Lung Injury (2) · Communicable Diseases (2) · Healthcare-Associated Pneumonia (2) · Infections (2) · Pneumonia, Bacterial (2) · Pneumonia, Ventilator-Associated (2) · Respiratory Tract Diseases (2) · Respiratory Tract Infections (2)
Infections (75) · Respiratory Tract Diseases (75) · Respiratory Tract Infections (75) · Lung Diseases (73) · Coronaviridae Infections (67) · Nidovirales Infections (67) · Pneumonia, Viral (67) · RNA Virus Infections (67) · Virus Diseases (64) · Coronavirus Infections (59) · Pathological Conditions, Signs and Symptoms (11) · Pathologic Processes (9) · Disease Attributes (7) · Bacterial Infections (5)
Standard of Care (3) · P5-22 and P14-44 drug combination (2) · RVM-V001 COVID-19 vaccine (2) · Sodium Chloride (2) · casirivimab (2) · casirivimab and imdevimab drug combination (2) · efineptakin alfa (2) · imdevimab (2) · nirmatrelvir (2) · sotrovimab (2) · 3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid (1) · ALT-803 (1) · AS03 adjuvant (1) · Acetylcysteine (1) · BDB001 (1)
ImmunityBio, Inc. (4) · Pfizer (3) · Innovent Biologics (Suzhou) Co. Ltd. (2) · Merck Sharp & Dohme LLC (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · RVAC Medicines (US), Inc. (2) · Regeneron Pharmaceuticals (2) · AbbVie (1) · Acerta Pharma BV (1) · Airway Therapeutics, Inc. (1) · Amanda Stapleton (1) · AstraZeneca (1) · Baptist Health South Florida (1) · Basilea Pharmaceutica (1) · Baylor College of Medicine (1)
United States (45) · Australia (4) · Brazil (4) · China (4) · Germany (3) · United Kingdom (3) · Austria (2) · Belgium (2) · Italy (2) · Mexico (2) · South Africa (2) · France (1) · Honduras (1) · India (1) · Japan (1)
Alpana Waghmare (1) · Amanda L Stapleton, MD (1) · Arunima Sarkar, MD (1) · Catherine H Marshall, MD/MPH (1) · Corey Casper, MD MPH (1) · Daniel Fowler, M.D. (1) · Esper Kallas, MD, PhD (1) · Ignacio Santos, MD (1)
PMID 34473343, PMID 34653525, PMID 34658014, PMID 35042081, PMID 35809371, PMID 36373249, PMID 39397784, PMID 39636474, PMID 39881564, PMID 41188882, PMID 41324898, PMID 41823072
2018 (1), 2023 (1), 272201300017C-18-0-1 (1), P30CA138292 (1), R44HL158446 (1)